Affiliation:
1. Department of Oncology, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang 455000, China
2. Department of Oncology, The General Hospital of Shenyang Military, Shenyang 110840, China
Abstract
Abstract
Objective
The objective of this retrospective study was to investigate the prognostic factors associated with survival among patients with extensive stage-small cell lung cancer (ES-SCLC).
Methods
Clinical data from 66 patients with ES-SCLC diagnosed via histopathology or cytology between July 2005 and July 2009 at Anyang Tumor Hospital (China) were analyzed. Univariate and multivariate Kaplan-Meier, log-rank, and Cox proportional hazard regression analyses were conducted.
Results
The 12-, 24-, and 36-month survival rates among patients with ES-SCLC were 40.9%, 13.6%, and 6.1%, respectively. The median survival time (MST) was 10 months. Univariate analyses indicated that weight loss, efficacy of first-line chemotherapy, total number of chemotherapy cycles, treatment method, and serum sodium levels significantly influenced survival among patients with ES-SCLC. Multivariate analyses suggested that the efficacy of first-line chemotherapy, total number of chemotherapy cycles, and serum sodium levels were independent prognostic factors associated with survival.
Conclusion
The efficacy of first-line chemotherapy, total number of chemotherapy cycles, and serum sodium levels are important prognostic factors for patients with ES-SCLC.
Publisher
Ovid Technologies (Wolters Kluwer Health)